Interestingly, a multicenter Phase II study evaluating the effect of infigratinib another selective FGFR1-3 inhibitor, recently demonstrates over a year of disease control in patients with tumours harbouring FGFR1/3 point mutations or FGFR3-TACC3 fusions [64]. This evidence concerns the gene FGFR3 and neoplasm.